U.S. Uterine Fibroid Market Accruals Reach Up to USD 39,993.2 Million by 2022 at 3.24% of CAGR; Declares MRFR

The report covers the Current scenario and the future growth prospects of the ‘U.S. Uterine Fibroid’ from 2018-2023. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Logo

Pune, India -- (SBWire) -- 06/19/2018 --Uterine Fibroids are the abnormal growth that gets developed inside or on the wall of a woman's uterus. These are also known as leiomyoma or myomas. The U.S. Uterine Fibroids Market is expected to reach USD 39,993.2 million by the end of the forecasted period and is expected to grow at a CAGR of 3.24%.

Uterine Fibroids are the abnormal growth that gets developed inside or on the wall of a woman's uterus. These are also known as leiomyoma or myomas. These are noncancerous growths that cause symptoms such as heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping, swelling enlargement of the abdomen. Increasing prevalence due to heredity and rising number of treatments to cure this disease has fuelled the growth of this market.

Uterine fibroids are the noncancerous growths of the uterus, which mostly appear during childbearing years. It is the abnormal growth of that gets developed inside or on the wall of a woman's uterus. Uterine fibroids is also known as myomas or leiomyomas. The symptom of uterine fibroids are frequent urination, constipation, backache, heavy menstrual bleeding, pelvic pressure, or menstrual periods lasting more than a week. The women with mild symptoms may go for medical treatments such as hormonal drugs, gonadotropin agonists, progestin and oral contraceptives. Women with moderate to severe symptoms may need surgery to treat uterine fibroids. According to the U.S. Department of Health and Human Services office on Women Health, about 20% to 80% of women develop fibroids by the age of 50 and nearly 30% will get them at the age of 35. Uterine fibroids are most common in women in their 40s and early 50s.

U.S. Uterine Fibroid Market – Key Finding

The U.S. Uterine Fibroid Market and is expected to reach USD 39,993.2 million by 2022.
By Type, Intramural Fibroids holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 14,972.5 million by 2022.
By Treatment, hysterectomy holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 8,042.3 million by 2022.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2394 .

U.S. Uterine Fibroid Market – Segments

U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners, Computed tomography (CT), Ultrasounds and others. On the basis of treatment the market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.

U.S. Uterine Fibroid Market - Key Players

Some of the key players in this market are:

AstraZeneca (England)
Cook Medical Inc. (US)
Boston Scientific Corporation (US)
GE Healthcare (U.K.)
AbbVie Inc. (U.S.)
Hologic (U.S.)

U.S. Uterine Fibroid Market - Competitive Analysis

Increasing incidence of uterine fibroid United States generate the interest of companies toward the market of uterine fibroid, as they feel there are huge opportunities and gaps between the market demand and supply of quality devices. Thus, companies are showing more interest in research and development activities for introducing the advanced treatment that meets the requirement of market. For instant, in Feb 2017, AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. Moreover, in Nov 2016, Boston Scientific Corporation Acquires Resectr Tissue Resection Device from Distal Access, LLC. The portfolio includes the Resectr Tissue Resection Device, a single-use solution designed to effectively remove uterine polyps.

The companies are introducing better devices for getting the leadership in the Uterine Fibroid devices market. Additionally company are focusing more into research and development activity in order to launch advanced device for the treatment of uterine fibroid. In this regard, GE today announced the launch of the Optima MR430s, a new specialty scanner with breakthrough technology that delivers precise imaging with exceptional comfort and the 1.5T image quality radiologists require. These invention help company to lead the market of uterine fibroid in United States.

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/2394 .

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued….

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.s

Media Relations Contact

Market Research Future
Executive
Market Research Future
646-845-9312
https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394

View this press release online at: http://rwire.com/993405